Delta-Fly Pharma Inc. Provides Schedule for Interim Analysis of Phase 3 Study of DFP-10917 in R/R AML

Delta-Fly Pharma Inc. has announced the schedule for the interim analysis of the Phase 3 study of DFP-10917 in relapsed/refractory acute myeloid leukemia (R/R AML) patients. The interim analysis will be based on outcome measurements including complete remission rate, overall survival, and safety. The first data processing is scheduled to be completed in mid-July 2023, followed by the second data..